Capricor Therapeutics
CAPR
$4.64
Share price
-3.13%
Change (1 day)
-5.69%
Change (1 year)
Categories
Capricor Therapeutics (CAPR) - P/B ratio
P/B ratio as of June 2024 : 8.05
According to Capricor Therapeutics
's latest financial reports the company has a price-to-book ratio of 8.05.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Capricor Therapeutics - P/B ratio (from 2002 to 2024)
P/B ratio by year
| Year | P/B ratio | Change |
|---|---|---|
| 2024-12-31 | N/A | -100% |
| 2023-12-31 | 6.66 | -19.41% |
| 2022-12-31 | 8.27 | 266.48% |
| 2021-12-31 | 2.26 | -9.3% |
| 2020-12-31 | 2.49 | 154.22% |
| 2019-12-31 | 0.9783 | -64.91% |
| 2018-12-31 | 2.79 | -22.94% |
| 2017-12-31 | 3.62 | -125.45% |
| 2016-12-31 | -14.2 | -70.64% |
| 2015-12-31 | -48.4 | 589.23% |
| 2014-12-31 | -7.03 | -90.11% |
| 2013-12-31 | -71.0 | -16674.27% |
| 2012-12-31 | 0.4285 | -98.36% |
| 2011-12-31 | 26.1 | 215.08% |
| 2010-12-31 | 8.27 | -24.77% |
| 2009-12-31 | 11.0 | 173.25% |
| 2008-12-31 | 4.02 | -53.88% |
| 2007-12-31 | 8.72 | -138.92% |
| 2006-12-31 | -22.4 | -64.56% |
| 2005-12-31 | -63.2 | -24.3% |
| 2004-12-31 | -83.5 | -11.76% |
| 2003-12-31 | -94.6 | -78.04% |
| 2002-12-31 | -431 |
P/B ratio for similar companies or competitors
| Company | P/B ratio | differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 5.06 | -37.15% | 🇺🇸 USA |
 Neurocrine Biosciences
NBIX | 5.70 | -29.22% | 🇺🇸 USA |
 Cytokinetics
CYTK | -15.6 | -294.29% | 🇺🇸 USA |
 Celldex Therapeutics CLDX | 2.85 | -64.64% | 🇺🇸 USA |
 Palatin Technologies PTN | 18.5 | 129.82% | 🇺🇸 USA |
 Eterna Therapeutics ERNA | -2.89 | -135.85% | 🇺🇸 USA |